Assertio Holdings Inc (ASRT)
1.36
+0.21
(+18.26%)
USD |
NASDAQ |
Jul 03, 16:00
Assertio Holdings Research and Development Expense (TTM): 3.576M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.576M |
| December 31, 2023 | 2.843M |
| September 30, 2023 | 1.819M |
| June 30, 2023 | 0.503M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 4.213M |
| September 30, 2020 | 9.558M |
| June 30, 2020 | 9.718M |
| March 31, 2020 | 9.355M |
| December 31, 2019 | 10.11M |
| September 30, 2019 | 6.739M |
| June 30, 2019 | 7.39M |
| March 31, 2019 | 8.307M |
| December 31, 2018 | 8.042M |
| September 30, 2018 | 31.99M |
| June 30, 2018 | 31.63M |
| March 31, 2018 | 35.06M |
| Date | Value |
|---|---|
| December 31, 2017 | 38.62M |
| September 30, 2017 | 21.61M |
| June 30, 2017 | 30.26M |
| March 31, 2017 | 31.77M |
| December 31, 2016 | 32.63M |
| September 30, 2016 | 84.72M |
| June 30, 2016 | 78.93M |
| March 31, 2016 | 76.53M |
| December 31, 2015 | 72.44M |
| September 30, 2015 | 13.23M |
| June 30, 2015 | 10.25M |
| March 31, 2015 | 6.932M |
| December 31, 2014 | 7.116M |
| September 30, 2014 | 7.107M |
| June 30, 2014 | 6.802M |
| March 31, 2014 | 6.817M |
| December 31, 2013 | 8.073M |
| September 30, 2013 | 9.234M |
| June 30, 2013 | 13.16M |
| March 31, 2013 | 15.28M |
| December 31, 2012 | 15.46M |
| September 30, 2012 | 15.06M |
| June 30, 2012 | 13.00M |
| March 31, 2012 | 13.52M |
| December 31, 2011 | 15.19M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
Mar 2023
10.11M
Maximum
Dec 2019
5.312M
Average
4.213M
Median
Dec 2020
Research and Development Expense (TTM) Benchmarks
| Nektar Therapeutics | 111.10M |
| Vertex Pharmaceuticals Inc | 3.209B |
| Verastem Inc | 67.05M |
| Cara Therapeutics Inc | 106.14M |
| Ocugen Inc | 36.84M |